Ticker
ADVM

Price
0.65
Stock movement down
-0.04 (-6.11%)
Company name
Adverum Biotechnologies Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
64.93M
Ent value
104.53M
Price/Sales
-
Price/Book
0.31
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-57.99%
3 year return
-60.28%
5 year return
-38.75%
10 year return
-
Last updated: 2023-01-31

DIVIDENDS

ADVM does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book0.31
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count99.73M
EPS (TTM)-1.57
FCF per share (TTM)-1.32

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-157.61M
Net income (TTM)-156.21M
EPS (TTM)-1.57
EPS (1y forward)-1.45

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash84.43M
Net receivables155.00K
Total current assets213.24M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment36.58M
Total assets332.36M
Accounts payable846.00K
Short/Current long term debt105.70M
Total current liabilities28.62M
Total liabilities124.03M
Shareholder's equity208.34M
Net tangible assets208.34M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-115.43M
Capital expenditures (TTM)15.98M
Free cash flow (TTM)-131.41M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-74.98%
Return on Assets-47.00%
Return on Invested Capital-71.14%
Cash Return on Invested Capital-59.85%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.71
Daily high0.72
Daily low0.65
Daily Volume1.44M
All-time high60.08
1y analyst estimate3.67
Beta0.75
EPS (TTM)-1.57
Dividend per share-
Ex-div date-
Next earnings date27 Mar 2023

Downside potential

Loading...
Downside potential data
ADVMS&P500
Current price drop from All-time high-98.92%-14.91%
Highest price drop-99.10%-56.47%
Date of highest drop27 Dec 20229 Mar 2009
Avg drop from high-82.42%-11.49%
Avg time to new high76 days13 days
Max time to new high2031 days1805 days
COMPANY DETAILS
ADVM (Adverum Biotechnologies Inc) company logo
Marketcap
64.93M
Marketcap category
Small-cap
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Employees
188
Investor relations
-
SEC filings
CEO
Leone D. Patterson
Country
USA
City
Redwood City
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
January 18, 2023
- First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023 - Cash runway into 2025 priori...
November 10, 2022
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in partic...
November 4, 2022
REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
October 27, 2022
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision...
September 30, 2022
REDWOOD CITY, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
September 27, 2022
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
September 23, 2022
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
September 23, 2022
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
September 23, 2022
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
September 15, 2022
Next page